

Luciana L Molinero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/414646/publications.pdf>

Version: 2024-02-01

10
papers

669
citations

1040056

9
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

1161
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	1.6	183
2	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. <i>Gynecologic Oncology</i> , 2019, 154, 314-322.	1.4	101
3	CARMA1 Controls an Early Checkpoint in the Thymic Development of FoxP3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2009, 182, 6736-6743.	0.8	99
4	High TCR Stimuli Prevent Induced Regulatory T Cell Differentiation in a NF- κ B-Dependent Manner. <i>Journal of Immunology</i> , 2011, 186, 4609-4617.	0.8	78
5	T cell-NF- κ B activation is required for tumor control in vivo. , 2015, 3, 1.		64
6	T cell receptor/CARMA1/NF- κ B signaling controls T-helper (Th) 17 differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18529-18534.	7.1	50
7	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 5631-5637.	7.0	31
8	Basal NF- κ B controls IL-7 responsiveness of quiescent naïve T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 7397-7402.	7.1	30
9	Cutting Edge: Engineering Active IKK β in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.8	18
10	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. <i>JCO Precision Oncology</i> , 2022, , .	3.0	15